ELISA F29 -A therapeutic efficacy biomarker in Chagas disease: Evaluation in pediatric patients treated with nifurtimox and followed for 4 years post-treatment.

• Κύριοι συγγραφείς: Rocio Rivero (Συγγραφέας), Mónica Inés Esteva (Συγγραφέας), Erya Huang (Συγγραφέας), Leylen Colmegna (Συγγραφέας), Jaime Altcheh (Συγγραφέας), Ulrike Grossmann (Συγγραφέας), Andrés Mariano Ruiz (Συγγραφέας), CHICO and CHICO SECURE Study Groups (Συγγραφέας)
• Μορφή: Βιβλίο
• Έκδοση: Public Library of Science (PLoS), 2023-06-01T00:00:00Z.
• Θέματα: article
• Διαθέσιμο Online: Connect to this object online.

<h4>Background</h4>Measurement of the success of antitrypanosomal treatment for Chagas disease is difficult, particularly in the chronic phase of the disease, because anti-Trypanosoma cruzi antibodies persist in serum for prolonged periods. We studied the effects of nifurtimox administer...